CN112190655A - Traditional Chinese medicine composition for treating hepatic sinus obstruction syndrome and application thereof - Google Patents

Traditional Chinese medicine composition for treating hepatic sinus obstruction syndrome and application thereof Download PDF

Info

Publication number
CN112190655A
CN112190655A CN202011272389.7A CN202011272389A CN112190655A CN 112190655 A CN112190655 A CN 112190655A CN 202011272389 A CN202011272389 A CN 202011272389A CN 112190655 A CN112190655 A CN 112190655A
Authority
CN
China
Prior art keywords
parts
traditional chinese
chinese medicine
obstruction syndrome
medicine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011272389.7A
Other languages
Chinese (zh)
Inventor
刘平
陈佳美
高思琦
刘伟
胡永红
付亚东
慕永平
张华�
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shuguang Hospital Affiliated to Shanghai University of TCM
Original Assignee
Shuguang Hospital Affiliated to Shanghai University of TCM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shuguang Hospital Affiliated to Shanghai University of TCM filed Critical Shuguang Hospital Affiliated to Shanghai University of TCM
Priority to CN202011272389.7A priority Critical patent/CN112190655A/en
Publication of CN112190655A publication Critical patent/CN112190655A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Abstract

The invention relates to a traditional Chinese medicine composition for treating liver sinus obstruction syndrome and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-15 parts of radix glehniae, 5-15 parts of radix ophiopogonis, 5-15 parts of angelica sinensis, 12-23 parts of radix rehmanniae recen, 10-14 parts of wolfberry fruit and 4-5 parts of szechwan chinaberry fruit. The invention also comprises application of the traditional Chinese medicine composition in preparing a medicine for treating liver sinus obstruction syndrome. The invention adopts animal experiments: the intervention effect of the traditional Chinese medicine formula on the monocrotaline-induced acute rat liver sinus obstruction syndrome is found, and the result shows that the traditional Chinese medicine formula can obviously improve the pathological change of the monocrotaline-induced rat liver sinus obstruction syndrome.

Description

Traditional Chinese medicine composition for treating hepatic sinus obstruction syndrome and application thereof
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating liver sinus obstruction syndrome and application thereof.
Background
Hepatic Sinus Obstruction Syndrome (HSOS), also known as Hepatic veno-occlusive obstruction (HVOD), is an intrahepatic portal hypertension syndrome in which the outflow tract of the Hepatic sinus is obstructed due to damage to the endothelial cells of the Hepatic sinus. Its main clinical manifestations include hepatomegaly, ascites, jaundice, and severe HSOS can progress to Multiple Organ Failure (MOF), with extremely high mortality rates. In europe and the united states, HSOS is one of the most common and serious complications that occur after Hematopoietic Stem Cell Transplantation (HSCT). In china, the ingestion of madder root containing the naturally toxic Pyrrolizidine Alkaloids (PAs) is the leading cause of HSOS. Currently, there is no clinically effective therapeutic agent, and only defibrotide currently available, approved in europe for the treatment of severe post-HSCT HSOS, has limitations in its treatment. The existing research shows that some active ingredients of the traditional Chinese medicine have the function of improving HSOS, such as sesamol, ligustrazine and the like, and the main action mechanism of the active ingredients is probably related to inflammation resistance and oxidation resistance.
The famous traditional Chinese medicine decoction (YIguanjiaan, YGJ) is from the 'Suming famous medical records' of Xianhui of Qing dynasty doctors, and consists of six traditional Chinese medicines of radix rehmanniae, radix ophiopogonis, radix glehniae, medlar, angelica and szechwan chinaberry fruit, and mainly treats the following diseases: hypochondriac pain, acid regurgitation, hernia and all liver diseases have the effects of nourishing yin and nourishing liver. Modern researches show that YGJ has good effect of resisting hepatic fibrosis, and the main action mechanism of YGJ is related to anti-inflammation, anti-oxidation, anti-hepatocyte injury, improving liver sinus capillary vascularization and inhibiting liver stellate cell activation. However, the intervention effect of YGJ on HSOS has not been reported.
It is well known to those skilled in the art that there are the following significant differences for sinus obstruction syndrome and liver fibrosis:
hepatic fibrosis is a pathological change existing in most chronic liver disease processes, and comprises various chronic liver diseases caused by hepatitis viruses, drugs and poisons, parasites, metabolism and heredity, cholestasis, immune abnormality and the like. It is mainly characterized by the excessive proliferation and deposition of the extracellular matrix (ECM) of the liver tissue, thereby causing the abnormal change of the liver tissue structure and influencing the normal physiological function of the liver, and the essence of the ECM is a reversible excessive repair reaction of the liver tissue injury in the process of chronic liver diseases. The continuous existence of hepatic fibrosis is accompanied by necrosis and apoptosis of normal parenchymal liver cells, ECM is accumulated continuously, and the liver parenchyma is gradually replaced by scar tissue formed by the ECM, finally, cirrhosis is formed, and even portal hypertension or liver cancer is generated, so that liver failure is caused. Activated Hepatic Stellate Cells (HSCs) are key cells for the generation of fibrous tissue.
The clinical manifestations of hepatic fibrosis patients are the clinical manifestations of primary chronic liver diseases, and the differences are large. Common clinical manifestations may be: tiredness, hypodynamia, inappetence, abnormal stool, discomfort or distension or pain in the liver area. Patients with liver cirrhosis may also have dark and gloomy complexion, spider nevus, hepatomegaly, splenomegaly, tongue with ecchymosis, etc. The pathological staining of the liver can show inflammatory manifestations, a large amount of collagen deposition, fibrosis in the area of the junction, capillary vascularization of the liver sinuses, even fibroseptal formation with vascular hyperplasia in the fibroseptal space, and the formation of scleronodules in severe cases.
Hepatic Sinus Obstruction Syndrome (HSOS) is a hepatic vascular disease in which endothelial cells of hepatic blood sinuses, hepatic venules and lobular intervenules are edematous, necrotic and shed to form microthrombosis, resulting in intrahepatic congestion, hepatic injury and portal hypertension. It is frequently occurred in europe after the pretreatment of bone marrow hematopoietic stem cell transplantation, and mostly caused by taking plants containing Pyrrole Alkaloid (PA) domestically, most commonly seen in madder root.
The clinical manifestations are abdominal distension, liver pain, anorexia, hypodynamia, ascites, jaundice, hepatomegaly, etc.; the typical pathological manifestations of the liver cancer are liver sinus endothelial cell swelling, damage and shedding which mainly comprise a liver acinus III area, and the liver sinus is obviously dilated and hyperemic; swelling and necrosis of liver cells in different degrees, infiltration of red blood cells into space, thickening of small hepatic vein wall, narrowing and occlusion of lumen, and no fibrosis or mild fibroplasia in the visible region of the junction.
Currently, there is no specific treatment for PA-HSOS. The treatment scheme mainly comprises stopping taking PA, and performing individualized treatment according to the disease condition. After the mild hospitalized patient stops contacting PA, the symptoms can be relieved and even recovered by self-recovery by carrying out symptomatic treatment such as liver protection and fluid infusion. For patients with mild symptoms, anticoagulant therapy, Transjugular Intrahepatic Portosystemic Shunt (TIPS), liver transplantation and the like are added on the basis of symptomatic treatment.
Thus, fibrosis is a pathological process that may occur in the non-acute phase of antral obstruction syndrome, and is not a characteristic change in HSOS. HSOS is mainly characterized by sinusoidal endothelial cell injury and hepatocellular necrosis, and fibrosis is characterized by stellate cell activation, collagen deposition and inflammatory response, which are different in etiology, pathology and diagnosis and treatment.
The patent discovers that the traditional Chinese medicine compound is used for treating the hepatic sinus obstruction syndrome for the first time, observes the intervention effect of the traditional Chinese medicine compound YGJ on acute rat HSOS (HSOS) induced by Monocrotaline (MCT), and discovers that the YGJ can obviously improve the rat HSOS induced by the MCT.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating liver sinus obstruction syndrome and application thereof aiming at the defects of the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that:
on one hand, the invention provides a traditional Chinese medicine composition for treating liver sinus obstruction syndrome, which comprises the following raw material medicines in parts by weight: 5-15 parts of radix glehniae, 5-15 parts of radix ophiopogonis, 5-15 parts of angelica sinensis, 13-23 parts of radix rehmanniae recen, 10-14 parts of wolfberry fruit and 4-5 parts of szechwan chinaberry fruit.
Preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight: 10 parts of coastal glehnia root, 10 parts of dwarf lilyturf tuber, 10 parts of Chinese angelica, 18 parts of dried rehmannia root, 12 parts of barbary wolfberry fruit and 4.5 parts of szechwan chinaberry fruit.
Further, the traditional Chinese medicine composition is prepared into a clinically acceptable pharmaceutical preparation according to a conventional traditional Chinese medicine preparation method.
Preferably, the pharmaceutical preparation is granules, powder, capsules, tablets, oral liquid or extract powder.
On the other hand, the invention provides the application of the traditional Chinese medicine composition in preparing a medicine for treating hepatic sinus obstruction syndrome.
Furthermore, the invention provides a medicine for treating liver sinus obstruction syndrome, which is prepared from the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary agents.
Furthermore, the invention provides extract powder for treating liver sinus obstruction syndrome, which is prepared from the traditional Chinese medicine composition, and the preparation method comprises the following steps:
taking raw material medicines, and respectively pulverizing the raw material medicines into powder;
(1) adding water with the dosage 8 times of that of the medicine, and decocting for three times;
(2) leaching out juice, combining the precipitates, and recovering and concentrating clear liquid under reduced pressure;
(3) freeze drying to obtain powder.
The invention has the advantages that:
the application of the traditional Chinese medicine compound YGJ in treating the hepatic sinus obstruction syndrome is proposed for the first time, and the observation of the intervention effect of the traditional Chinese medicine compound YGJ on the monocrotaline-induced acute rat HSOS shows that the YGJ intervention can obviously reduce the serum ALT and AST levels of the MCT-induced rat, relieve the hepatocyte necrosis and the extravasated blood phenomenon of the MCT-induced rat and obviously improve the lesion degree of the MCT-induced hepatic sinus endothelial injury of the rat. It was shown that YGJ could significantly improve MCT-induced hepatocyte damage and pathological changes in HSOS. The suggestion shows that the traditional Chinese medicine compound YGJ can be used for treating the hepatic sinus obstruction syndrome, provides a new treatment scheme for the patients, relieves the pain of the patients, and has strong practicability and wide application prospect.
Drawings
FIG. 1 is the effect of YGJ on MCT-induced HSOS blood biochemical and pathological changes, note: a: ALT and AST levels; b: HE dyeColor (× 200); c: liver tissue scanning electron microscopy results (20000 ×).*p<0.05,**p<0.01,***p<0.001. N, normal control group; m, a model group; YGJ, group of Yiguan Jian.
Detailed Description
The invention will be further illustrated with reference to specific embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes and modifications can be made by those skilled in the art after reading the disclosure of the present invention, and equivalents fall within the scope of the appended claims.
EXAMPLE 1 Chinese medicinal composition 1
Taking the following raw materials in parts by weight: 5 parts of coastal glehnia root, 5 parts of dwarf lilyturf tuber, 5 parts of Chinese angelica, 13 parts of dried rehmannia root, 10 parts of medlar and 4 parts of szechwan chinaberry fruit.
EXAMPLE 2 Chinese medicinal composition (II)
Taking the following raw materials in parts by weight: 15 parts of coastal glehnia root, 15 parts of dwarf lilyturf tuber, 15 parts of Chinese angelica, 23 parts of raw rehmannia root, 14 parts of barbary wolfberry fruit and 5 parts of szechwan chinaberry fruit.
EXAMPLE 3 Chinese medicinal composition (III)
Taking the following raw materials in parts by weight: 5 parts of coastal glehnia root, 15 parts of dwarf lilyturf tuber, 5 parts of Chinese angelica, 23 parts of raw rehmannia root, 10 parts of barbary wolfberry fruit and 5 parts of szechwan chinaberry fruit.
EXAMPLE 4 Chinese medicinal composition (IV)
Taking the following raw materials in parts by weight: 15 parts of coastal glehnia root, 5 parts of dwarf lilyturf tuber, 15 parts of Chinese angelica, 13 parts of dried rehmannia root, 14 parts of barbary wolfberry fruit and 4 parts of szechwan chinaberry fruit.
EXAMPLE 5 Chinese medicinal composition (V)
Taking the following raw materials in parts by weight: 5 parts of coastal glehnia root, 5 parts of dwarf lilyturf tuber, 5 parts of Chinese angelica, 23 parts of raw rehmannia root, 14 parts of barbary wolfberry fruit and 5 parts of szechwan chinaberry fruit.
EXAMPLE 6 Chinese medicinal composition (VI)
Taking the following raw materials in parts by weight: 15 parts of coastal glehnia root, 15 parts of dwarf lilyturf tuber, 15 parts of Chinese angelica, 13 parts of dried rehmannia root, 10 parts of medlar and 4 parts of szechwan chinaberry fruit.
EXAMPLE 7 Chinese medicinal composition (seven)
Taking the following raw materials in parts by weight: 10 parts of coastal glehnia root, 10 parts of dwarf lilyturf tuber, 10 parts of Chinese angelica, 18 parts of dried rehmannia root, 12 parts of barbary wolfberry fruit and 4.5 parts of szechwan chinaberry fruit.
Example 8 decoction
The preparation method comprises the following steps: the raw materials are respectively taken according to any one of the weight parts in the embodiments 1-7, a proper amount of water is added for decoction, the decoction is carried out for three times, and the filtrates are combined.
Example 9 granules
The preparation method comprises the following steps: respectively taking the raw materials according to any one of the weight parts of the embodiments 1-7, respectively pulverizing the raw materials, adding 8 times of water for decocting for three times, draining the juice, precipitating, combining the clear liquid, recovering and concentrating under reduced pressure to obtain clear paste, and taking the clear paste and the auxiliary agent of the granules to prepare the granules according to a conventional preparation method.
EXAMPLE 10 extract powder
The preparation method comprises the following steps: respectively taking the raw materials according to any one of the weight parts of the embodiments 1-6, respectively pulverizing the raw materials into powder, adding 8 times of water for decocting for three times, draining the juice, combining the precipitates and the clear liquid, recovering and concentrating under reduced pressure, and freeze-drying the precipitates into powder to obtain the traditional Chinese medicine composition.
Example 11 animal experiments
1. Material
1.1 animals
SPF grade male Sprague-Dawley (SD) rats (weight: 180-. The feed is raised in the experimental animal center of Shanghai medical university, and the feed can be freely drunk, and the feed has constant temperature and humidity and can be alternated day and night. The animal experiments were approved by the university of medicine laboratory animal ethics committee in shanghai (university of medicine animal laboratory guide in shanghai) (No. pzshutcm 190315007).
2. Method of producing a composite material
2.1 preparation of the drug
YGJ extract powder: 10g (1.0kg) of radix glehniae, 10g (1.0kg) of radix ophiopogonis, 10g (1.0kg) of angelica sinensis, 18g (1.8kg) of radix rehmanniae recen, 12g (1.2kg) of wolfberry fruit and 4.5g (0.45kg) of szechwan Chinaberry fruit. Pulverizing 6 medicinal materials into powder, adding appropriate amount of water (8 times amount), decocting for three times, mixing filtrates, recovering under reduced pressure, concentrating, freeze drying to obtain YGJ water extract powder, and storing in a shady and cool drier for use, wherein the extract powder per g is equal to 3.021g of crude drug according to the yield. The medicine is prepared at one time by the preparation center of the subsidiary eosin Hospital of Shanghai medicine university (third-level laboratory of State administration of traditional Chinese medicine), and all the decoction pieces are reserved for sample preparation. MCT was added to distilled water and titrated to pH 3.0 with 0.1N HCl to completely dissolve the solid. Subsequently, the solution was neutralized to pH 7.0 using 0.5n naoh, formulated prior to use.
2.2 animal model preparation and group administration
SD rats were adaptively bred and then randomly divided into 3 groups of 10 animals per group based on body weight, and a rat HSOS model was prepared by intragastric gazing rats with 90mg/kg MCT. The gavage is carried out according to groups respectively, and the liquid medicine for gavage is 10 ml/kg. When the MCT gavage was scored as 0, the following were administered: normal group (N); model group (MCT): MCT is perfused once at 0; yiguan fried group (YGJ): the dosage is 1.139g/kg, MCT is used for intragastric administration once at 0, and YGJ is used for intragastric administration twice at 6 hours and 30 hours. After 48 hours, the material was sacrificed after anesthesia by intraperitoneal injection with 3% sodium pentobarbital, and blood (serum was obtained by standing for 3 hours and centrifuging at 1000g/min for 15 min) and liver tissue samples were collected for subsequent experiments.
2.3 Biochemical analysis of serum
Unfreezing a serum sample at room temperature, uniformly mixing the unfrozen serum sample with vibration, and sequentially putting the unfrozen serum sample into a full-automatic analyzer according to the sequence of labels; and adding corresponding AST and AST reagents into a detection reagent bottle of the analyzer, and detecting the AST and AST activity according to the steps of a kit instruction.
2.4 histopathological Observation
The liver tissue of the same part of the liver large leaf is taken and placed in 10% neutral formaldehyde buffer solution for fixation, the dehydration is carried out by an automatic dehydrator, the paraffin embedding and the slicing are carried out, the H & E staining is carried out, the sealed slice is automatically scanned by a data slice scanner, and the damage of the liver cell, the inflammatory reaction degree and the like are observed.
2.5 scanning Electron microscope Observation
Perfusion was first performed through the abdominal aorta with PBS and then with a fixing solution containing 2.5% glutaraldehyde. Then the liver is treatedCutting the dirty into small pieces (about 5 mm)3) Fixing with 2% glutaraldehyde for 2-3 hr, washing with 0.1M PBS for 3 times, 30 min/time, fixing with 1% osmic acid for 2 hr, washing with 0.1M PBS for 3 times, dehydrating with 30 min/time, 30%, 50%, 70%, 90%, 100% alcohol gradient, displacing with intermediate solution, drying the specimen in critical point dryer (Germany Leica CPD 300), and sticking the dried specimen on special sample stage with double-sided adhesive tape. The sample stage was then placed in an ion sputtering apparatus (Leica EMACE600, produced by Austria Leica Microsystems) for surface gold plating. Next, the sample stage (with the specimen on the stage) was observed by a scanning electron microscope (QUANTA FEG 250 environmental scanning electron microscope, manufactured by Philips, Netherlands).
2.6 statistical analysis
The statistical method adopts SPSS 20.0 software to carry out statistical analysis on data, non-parameter test is adopted for metering data, the data are expressed as standard deviation of mean value plus or minus mean value, One-way ANOVA is adopted for multiple comparison analysis among groups and LSD is combined for multiple comparison analysis, and P <0.05 is used as difference and has statistical significance.
3. Results
3.1 MCT-induced pathological changes in rat HSOS and intervention in pan-decoction
The serum ALT and AST activities were significantly increased in the model group compared to the normal control group (p <0.001), and the YGJ group significantly decreased MCT-induced serum ALT and AST levels (p <0.05) (see fig. 1 a). The H & E staining of the liver tissue shows that the lobular structure of the liver in the normal group is clear, the liver plates are arranged regularly, the area of the sink is not enlarged, and inflammatory cells are not infiltrated. The model group shows that a large amount of liver cells are necrosed, inflammatory cells around a junction area are infiltrated, red blood cells in liver sinuses are gathered in a large amount, the phenomenon of 'congestion' is obvious, and the damage of a liver structure is serious; the YGJ group showed significantly reduced phenomena of hepatocyte necrosis and "congestion" (see FIG. 1 b). In addition, the results of a liver tissue scanning electron microscope show that compared with the normal group, the liver blood sinus of the model group is expanded, the endothelial window hole of the liver sinus is enlarged, and the sieve-shaped structure disappears and even falls off, so that the space of the space is exposed; the YGJ group showed significantly improved lesions of liver sinusoidal endothelial injury compared to the model control rats (see FIG. 1 c). YGJ was shown to significantly improve MCT-induced hepatocyte damage and pathological changes in HSOS.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and additions can be made without departing from the principle of the present invention, and these should also be considered as the protection scope of the present invention.

Claims (7)

1. The traditional Chinese medicine composition for treating liver sinus obstruction syndrome is characterized by comprising the following raw material medicines in parts by weight: 5-15 parts of radix glehniae, 5-15 parts of radix ophiopogonis, 5-15 parts of angelica sinensis, 13-23 parts of radix rehmanniae recen, 10-14 parts of wolfberry fruit and 4-5 parts of szechwan chinaberry fruit.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 10 parts of coastal glehnia root, 10 parts of dwarf lilyturf tuber, 10 parts of Chinese angelica, 18 parts of dried rehmannia root, 12 parts of barbary wolfberry fruit and 4.5 parts of szechwan chinaberry fruit.
3. The Chinese medicinal composition according to any one of claims 1 to 2, which is prepared into a clinically acceptable medicinal preparation according to a conventional Chinese medicinal preparation method.
4. The traditional Chinese medicine composition of claim 3, wherein the pharmaceutical preparation is granules, powder, capsules, tablets, oral liquid or extract powder.
5. Use of a Chinese medicinal composition according to any one of claims 1-2 in the manufacture of a medicament for the treatment of hepatic sinus obstruction syndrome.
6. A medicament for treating hepatic sinus obstruction syndrome, wherein the medicament is prepared from the Chinese medicinal composition of claim 1 and pharmaceutically acceptable adjuvants.
7. An extract powder for treating liver sinus obstruction syndrome, which is characterized in that the extract powder is prepared from the traditional Chinese medicine composition of claim 1, and the preparation method comprises the following steps:
(1) taking raw material medicines, and respectively pulverizing the raw material medicines into powder;
(2) adding water with the dosage 8 times of that of the medicine, and decocting for three times;
(3) leaching out juice, combining the precipitates, and recovering and concentrating clear liquid under reduced pressure;
(4) freeze drying to obtain powder.
CN202011272389.7A 2020-11-13 2020-11-13 Traditional Chinese medicine composition for treating hepatic sinus obstruction syndrome and application thereof Pending CN112190655A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011272389.7A CN112190655A (en) 2020-11-13 2020-11-13 Traditional Chinese medicine composition for treating hepatic sinus obstruction syndrome and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011272389.7A CN112190655A (en) 2020-11-13 2020-11-13 Traditional Chinese medicine composition for treating hepatic sinus obstruction syndrome and application thereof

Publications (1)

Publication Number Publication Date
CN112190655A true CN112190655A (en) 2021-01-08

Family

ID=74034265

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011272389.7A Pending CN112190655A (en) 2020-11-13 2020-11-13 Traditional Chinese medicine composition for treating hepatic sinus obstruction syndrome and application thereof

Country Status (1)

Country Link
CN (1) CN112190655A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1843456A (en) * 2005-04-07 2006-10-11 孙毅 Method for extracting polysaccharide from Chinese formula of 'Yi Guan Jian'
CN102028861A (en) * 2009-09-24 2011-04-27 周艳 New liver and kidney nourishing decoction preparation (novel medicament delivery system) and preparation method thereof
CN103156997A (en) * 2011-12-16 2013-06-19 上海中医药大学附属曙光医院 Composition of effective parts of traditional Chinese medicines for treating chronic hepatopathy, preparation method and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1843456A (en) * 2005-04-07 2006-10-11 孙毅 Method for extracting polysaccharide from Chinese formula of 'Yi Guan Jian'
CN102028861A (en) * 2009-09-24 2011-04-27 周艳 New liver and kidney nourishing decoction preparation (novel medicament delivery system) and preparation method thereof
CN103156997A (en) * 2011-12-16 2013-06-19 上海中医药大学附属曙光医院 Composition of effective parts of traditional Chinese medicines for treating chronic hepatopathy, preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
石远凯: "《中国肿瘤内科进展中国肿瘤医师教育.2017年》", 31 July 2017, 中国协和医科大学出版社 *
群瑛: "《养生保健必备》", 30 June 2007, 中国戏剧出版社 *

Similar Documents

Publication Publication Date Title
ZA200608606B (en) Traditional Chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method
CN101011452A (en) Plant extract with hypotensive effect and its preparing process and use
CN103301179B (en) Application of eucommia ulmoides lignan extract in preparing PPARalpha agonist
CN112190655A (en) Traditional Chinese medicine composition for treating hepatic sinus obstruction syndrome and application thereof
CN101574410B (en) Effective components of peony leaves as well as preparation method and application thereof
CN102755405B (en) Fructus crataegi leaf water extract, preparation containing same and preparation method pf fructus crataegi leaf water extract
CN101849997B (en) Traditional Chinese medicine composition capable of reducing blood pressure and tonifying kidney and preparation method and application thereof
CN102309542A (en) Orthosiphon n-butanol fraction medicine for treating chronic nephritis and preparation method thereof
CN101632726B (en) Application of Chinese medicinal composition in preparing medicament for treating blood vessel micro-embolization
CN101152234B (en) Application of cortex eucommiae lignans and its extract in against cardiovascular reconstruction
CN1250253C (en) Chinese medicine capsule for treating ischemic cerebral apoplexy
CN108542926A (en) The preparation method and pharmaceutical composition of a kind of purslane extract and its application
CN101342236B (en) Method for preparing red sage root extract, red sage root extract and medicament composition containing the same
CN104161850A (en) Preparation method of Chinese herbal extract, prepared Chinese herbal extract and application
CN103665180A (en) Application of Morindae officinalis oligosaccharide 6 glycan in preparation of myocardial ischemia and reperfusion injury resistance medicines
CN114588212A (en) New use of traditional Chinese medicine water lettuce for resisting heart failure
CN104435067B (en) A kind of Cortex Eucommiae components composition and preparation thereof with myocardium protecting action
CN109512847A (en) Plumbago zeylanica is in the purposes being used to prepare in treatment pulmonary fibrosis disease drug
CN113244351A (en) Traditional Chinese medicine composition for treating coronary heart disease and preparation method and application thereof
CN109568471B (en) Compound preparation of fucoidan sulfate from Laminaria japonica with hypoglycemic effect
CN114404403B (en) Application of alpinetin in preparation of medicines for treating myocardial infarction and myocardial remodeling after myocardial infarction
CN105250352A (en) Application of eucommia ulmoides lignan extract in preparation of PH (pulmonary hypertension) treatment drug
CN106923315B (en) Black fungus lignan extract and preparation method and application thereof
CN101675946B (en) Application of a traditional Chinese medicine in preparing a medicine for reducing inflammatory reaction after PCI
CN107184760B (en) Chinese medicinal composition for treating cardiovascular diseases and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210108